In vitro the differences of inflammatory and oxidative reactions due to sulfur mustard induced acute pulmonary injury underlying intraperitoneal injection and intratracheal instillation in rats.

This study was to investigate the differences of inflammatory reaction and oxidative stress due to sulfur mustard (SM)-induced acute pulmonary injury via two ways in rats. In intraperitoneal and tracheal SM groups, injected intraperitoneally and instilled intratracheally with 0.1mL diluted SM (0.96 LD50=8mg/kg) and SM (0.98 LD50=2mg/kg) were administered in rats. In bronchoalveolar lavage fluid, serum, and alveolar septum, lactate dehydrogenase, glutathione peroxidase, tumor necrosis factor-α, interleukin-1ß, interleukin-6, C-reactive protein, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, l-selectin, r-glutamyl transpeptidase, thiobarbituric acid reactive substances levels as well as the expression of CD4, CD20, CD68, 8-hydroxy deoxyguanosine, nuclear factor-E2-related factor 2, and heme oxygenase-1 measured by ELISA, immune scatter turbidimetry and immunohistochemical method in the intraperitoneal SM group were increased at each time-point compared with the tracheal SM groups, respectively. These data demonstrated an increased inflammatory reaction and oxidative stress indices in rat via intraperitoneal injection under similar SM LD50 doses.

Emergency clinical laboratory system for civilian and military uses in actual military operations / 医疗卫生装备

Objective To develop an emergency clinical laboratory system for civilian and military uses to enhance medical support of filed medical unit for mass casualties.Methods The missions of field medical unit were analyzed in the actual confrontation,and an emergency clinical laboratory system for civilian and military uses was built to fulfill clinical laboratory support.The factors were explored for clinical laboratory examination,and some measures were taken accordingly.Results The requirements of field medical unit were met by the developed system.Conclusion The system can be applied in largescale military exercises to enhance clinical laboratory support ability of field medical unit.

Status of AMH in Serum of Healthy Women in Shenzhen Area and Its Value in PCOS and POF Treatment / 现代检验医学杂志

Objective To investigate the current status of anti-mullerian hormone (AMH) in healthy women in the healthy childbearing age in Shenzhen area,and to explore its application value in polycystic ovary syndrome (PCOS) and prature ovarian syndrome (POF) treatment.Methods Collected 860 cases of medical health women of childbearing age in Shenzhen BaoanDistrict People's Hospital from January 2016 to March 2017 as control group,and at the same time selected 59 cases of patients with PCOS and 61 cases of patients with POF as observation group.Adopted DXI800 chemiluminescence analyzer to test serum AMH level of control group,patients with PCOS and POF group respectively before and 3 months after treatment,and the testing results were analyzed.Results The serum AMH level of Healthy women of childbearing age was 4.91 ±1.56 ng/ml,18～25 years old group was 5.38±1.27 ng/ml,31～35 and 36～42 years old group were 4.53±1.40 ng/ml and 3.95±1.16 ng/ml,being all lower than that in group 18～25 years old (t=3.082,5.066,all P＜0.05).While 26～30 years old group was 5.09± 1.45 ng/ml,and compared with 18～ 25,there was no statistically significant difference (t=0.892,P＞0.05).Before the treatment,the serum AMH level of PCOS was 10.13± 3.85 ng/ml,significantly higher than the control group,the difference was statistically significant (t=13.924,P＜0.01),while the serum AMH level of POF group and wait POF patients were 1.04±0.37 ng/ml and 2.39±0.87 ng/ml,significantly lower than the control group (t=10.913,8.042,all P＜0.05),and POF lower than wait POF group (t=2.875,P＜0.05).After treatment,the serum AMH level of PCOS was 5.22± 1.58 ng/ml,significantly lower than before treatment (t =11.106,P＜0.05),and there was no statistically significant difference between control group (t=1.036,P＞0.05),the serum AMH level of POF and wait POF were 4.49±1.32 ng/ml and 4.54± 1.47 ng/ml,significantly higher than the before treatment (t=9.608,7.253,all P＜0.05),and compared with the control group there were no statistically significant differences (t =1.209,0.918,all P＞0.05).Conclusion Before the treatment,the serum AMH levels of PCOS were increased significantly,and the serum AMH levels of POF and wait POF patients were significantly reduced,while the serum AMH levels of PCOS,POF and wait POF patients were all restored to normal levels after treatment.Therefore,AMH has certain application value in the diagnosis and treatment evaluation of women PCOS and POF disease.

Skin decontamination efficacy of potassium ketoxime on rabbits exposed to sulfur mustard.

CONTEXT: The chemical weapon sulfur mustard (SM) is a blister agent, and currently, there is no effective antidote. OBJECTIVE: To evaluate the decontamination efficacy of potassium ketoxime against SM and preliminarily elucidate its decontamination mechanism. MATERIALS AND METHODS: Potassium ketoxime reacted with SM, and SM residues were tested at different time intervals by T-135 colorimetry after the reaction. Rabbit skin was topically exposed to 2 mg/cm(2) SM, treated with potassium ketoxime 1 min later, and observed after 6, 12, and 24 h. Gas chromatography-mass spectroscopy was employed to screen and identify the main products of potassium ketoxime decontamination of SM. RESULTS: Potassium ketoxime had a great effect against SM contamination. With a mass ratio of decontaminant: SM of 50:1, decontamination rates against SM were 87.5% after 30 s, 95.9% after 1 min, and 99.0% after 5 min. Fifteen minutes after exposure to SM, the untreated group showed clear erythema lesions, whereas the experimental group showed no clear erythema lesions within 6 h. After 12 and 24 h, the areas of damaged skin in the experimental group were 0.038 and 0.125 cm(2), respectively, compared with 2.21 and 2.65 cm(2) in the control group. Histopathological analysis revealed that treatment with potassium ketoxime also reduced inflammation-induced damage. CONCLUSION: The results of this study indicate that potassium ketoxime reacted rapidly and completely with SM, and thus, it was found to be a suitable and effective skin decontaminant against SM. The decontamination reaction mechanism is mainly related to nucleophilic substitution.

Effect of arcuate keratomy on decreasing astigmatism in lOL implantation after intracapsular cataract extraction / 国际眼科杂志(Guoji Yanke Zazhi)

AlM: To study an approach to visual acuity correction after intracapsular cataract extraction by phase - ll intraocular lens implantation through the individualized arcuate keratotomy. METHODS: For demonstration, 48 postoperative patients ( 50 eyes ) receiving the intracapsular cataract extraction were gathered up. Each patient received a scleral tunnel major incision along the radial line of the maximum corneal refractive power determined by a cornea curvimeter, and a arcuate keratotomy was made opposite to the major one; through the major incision an iris-claw intraocular lens is implanted. Each patient was measured for their corneal astigmatism and uncorrected visual acuity before and after the surgery. RESULTS: The results suggested the average corneal astigmatism before the surgery and that 3d, 1, 3, 6 and 12mo after the surgery as+3. 18±0. 68,-1. 56±0. 73,+0. 87± 0. 51, + 1. 21 ± 0. 70, + 1. 33 ± 0. 68 and + 1. 48 ± 0. 48 respectively. The uncorrected visual acuities 3d, 1, 3, 6 and 12mo after the surgery are 0. 5±0. 38, 0. 56±0. 23, 0. 55± 0. 24, 0. 52±0. 28 and 0. 51±0. 25 respectively. CONCLUSlON: Phase-ll intraocular lens implantation witharcuate keratotomy is helpful to improve the postoperative visual acuity and reduce preoperative corneal astigmatism after the intracapsular cataract extraction aphakic eyes, lt is also a low-cost surgery, and easy to perform, with minor surgical injuries, particularly available for surgical visual acuity correction of the aphakic eye receiving intracapsular cataract extraction.

A three-plasmid system for construction of armed oncolytic adenovirus.

There is growing interest in the use of oncolytic virus as a tool in cancer gene therapy. However, construction of oncolytic adenovirus (Ad) is not an easy task due to lack of convenient, robust methods. A three-plasmid system was introduced for construction of armed oncolytic Ad. Besides the pShuttle-CMV and pAdEasy-1, a third plasmid (pTE-ME1), harboring the E1 region of Ad5, was generated and included in this system. In pTE-ME1, the promoter of E1A was deleted and replaced with a multiple-cloning site (MCS). A therapeutic gene and tissue-specific promoter (TSP) could be inserted routinely into the MCS of pShuttle-CMV and pTE-ME1, respectively. The modified E1 region could then be excised from pTE-ME1 and integrated into the therapeutic gene-containing pShuttle-CMV to form the final shuttle plasmid. This shuttle plasmid was recombined with pAdEasy-1 in Escherichia coli strain BJ5183 to generate Ad plasmid. Finally, the oncolytic Ad could be rescued in Ad plasmid-transfected packaging cells. The GFP gene and the promoter of telomerase reverse transcriptase (TERTp) were chosen as the transgene and TSP, respectively, to test this system. Two oncolytic Ads, Ad-GFP-TPE and Ad-GFP-D19K, were generated successfully. Their oncolytic and replicating abilities were investigated in TERT-positive tumor cells. The results suggest that the three-plasmid system was practicable and could be used to construct other transcriptionally regulated oncolytic Ads carrying a therapeutic gene.